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atric endocrinology were allocated to working groups with 
assigned topics and specific questions. Each group 
searched the literature, evaluated the evidence, and devel-
oped a draft document. These papers were debated and 
finalized by each group before presentation to the full as-
sembly for further discussion and agreement.  Recommen-
dations: The recommendations include: worldwide neo-
natal screening, approaches to assess the cause (including 
genotyping) and the severity of the disorder, the immedi-
ate initiation of appropriate L-T 4 supplementation and
 Abstract 
 Objective: The aim was to formulate practice guidelines for 
the diagnosis and management of congenital hypothy-
roidism (CH).  Evidence: A systematic literature search was 
conducted to identify key articles relating to the screening, 
diagnosis, and management of CH. The evidence-based 
guidelines were developed with the Grading of Recom-
mendations, Assessment, Development and Evaluation 
(GRADE) system, describing both the strength of recom-
mendations and the quality of evidence. In the absence of 
sufficient evidence, conclusions were based on expert 
opinion.  Consensus Process: Thirty-two participants drawn 
from the European Society for Paediatric Endocrinology 
and five other major scientific societies in the field of pedi-
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frequent monitoring to ensure dose adjustments to keep 
thyroid hormone levels in the target ranges, a trial of
treatment in patients suspected of transient CH, regular as-
sessments of developmental and neurosensory functions, 
consulting health professionals as appropriate, and educa-
tion about CH. The harmonization of diagnosis, manage-
ment, and routine health surveillance would not only opti-
mize patient outcomes, but should also facilitate epidemi-
ological studies of the disorder. Individuals with CH require 
monitoring throughout their lives, particularly during early 
childhood and pregnancy. © 2014 S. Karger AG, Basel
 and The Endocrine Society
 Summary of Recommendations
1.1 The benefits of congenital hypothyroidism 
screening 
 • Early detection and treatment of congenital hypothy-
roidism (CH) through neonatal screening prevents 
neurodevelopmental disability and optimizes devel-
opmental outcomes (1 ∣ ⊕ ⊕ ⊕ ). 
 1.2 Analytical methodology, effectiveness, and 
efficacy of CH screening strategies 
 • Screening for primary CH should be introduced world-
wide. The initial priority of neonatal screening for CH 
should be the detection of all forms of primary CH: 
mild, moderate, and severe. The most sensitive test for 
detecting primary CH is TSH determination (1 ∣ ⊕ ⊕ ⊕ ). 
 1.3 Screening in special categories of neonates at 
risk of CH 
 • A strategy of second screening should be considered 
for the following conditions: preterm neonates; low-
birth weight (LBW) and very low-birth weight (VLBW) 
neonates; ill and preterm newborns admitted to neo-
natal intensive care units (NICU); specimen collection 
within the first 24 hours of life; and multiple births 
(particularly same-sex twins); (2 ∣ ⊕ ⊕ ⚪ ). 
 2.1 Biochemical criteria used in the decision to 
initiate treatment  
 • If capillary TSH concentration from blood obtained 
on neonatal screening is  ≥ 40 mU/l whole blood, we 
recommend starting treatment as soon as a good ve-
nous sample can be obtained, without waiting for the 
venous blood test result, unless venous thyroid func-
tion test (TFT) results are available on the same day 
(1 ∣ ⊕ ⊕ ⚪ ). 
 • If capillary TSH concentration is <40 mU/l of whole 
blood, the clinician may wait for the results of venous 
TFT, provided that these results are available on the 
following day (1 ∣ ⊕ ⊕ ⚪ ).  
 2.2 Communication of elevated TSH result  
 • The detection of a high TSH concentration on screen-
ing should be communicated by an experienced
person (e.g. screening laboratory staff or pediatric 
endocrine team) either by telephone or in person 
(2 ∣ ⊕ ⚪ ⚪ ).  
 • When the child reaches nursery or school age, educa-
tors and teachers need not be informed about the child 
having CH to avoid stigmatization due to ‘labeling’ 
(2 ∣ ⊕ ⚪ ⚪ ).  
 2.3 Decision to start treatment on the basis of 
venous TFTs  
 • If venous free T 4 (FT4) concentration is below norms 
for age, treatment should be started immediately 
(1 ∣ ⊕ ⊕ ⊕ ).  
 • If venous TSH concentration is >20 mU/l, treatment 
should be started, even if FT4 concentration is normal 
(2 ∣ ⊕ ⊕ ⚪ ).  
Abbreviations used in this paper
CCH central CH
CH congenital hypothyroidism
DBS dried blood spot
FT4 free T4
GA gestational age
HrQOL health-related quality of life
LBW low birth weight
L-T4 levothyroxine
NICU neonatal intensive care units
NIS sodium/iodide symporter
T4 thyroxine
TFT thyroid function text
TT4 total T4
VLBW very low birth weight
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 • If venous TSH concentration is  ≥ 6 to 20 mU/l beyond 
21 days in a well baby with a FT4 concentration within 
the limits for age, we suggest (a) investigation, which 
should include diagnostic imaging, to try to obtain a 
definitive diagnosis; (b) consideration, in discussion 
with the family, of either initiating thyroxine supple-
mentation immediately and retesting, off treatment, at 
a later stage; or withholding treatment but retesting 
two weeks later (2 ∣ ⊕ ⊕ ⚪ ). 
 2.4 Use of imaging in assessing the severity and 
cause of CH 
 • X-ray of the knee may be carried out to assess the se-
verity of intrauterine hypothyroidism by the presence 
or absence of femoral and tibial epiphyses (2 ∣ ⊕ ⊕ ⊕ ).  
 • The thyroid gland should be imaged using either ra-
dioisotope scanning (scintigraphy) with or without 
the perchlorate discharge test; or ultrasonography; or 
both (1 ∣ ⊕ ⊕ ⚪ ).  
 • Imaging should never be allowed to delay the initiation 
of treatment (1 ∣ ⊕ ⊕ ⚪ ).  
 2.5 Associated malformations and syndromes  
 • All neonates with high TSH concentrations should be 
examined carefully for congenital malformations (par-
ticularly cardiac) and for dysmorphic features (1 ∣ ⊕ ⊕ ⊕ ). 
 3.1 Treatment and monitoring of CH  
 • L-T 4 alone is recommended as the medication of 
choice for treating CH (1 ∣ ⊕ ⊕ ⚪ ).  
 • L-T 4 treatment should be initiated as soon as possible 
and no later than 2 weeks after birth or immediately 
after confirmatory serum test results in infants in 
whom CH is detected by a second routine screening 
test (1 ∣ ⊕ ⊕ ⚪ ).  
 • An initial L-T4 dose of 10–15 μg/kg per day should be 
given (1 ∣ ⊕ ⊕ ⚪ ).  
 • Infants with severe disease, as defined by a very low 
pretreatment TT 4 or FT4 concentration, should be 
treated with the highest initial dose (1 ∣ ⊕ ⊕ ⚪ ).  
 • L-T 4 should be administered orally; if intravenous 
treatment is necessary the dose should be no more than 
80% of the oral dose. The dose should then be adjusted 
according to TSH and FT4 determinations (1 ∣ ⊕ ⊕ ⚪ ).  
 • L-T 4 tablets should be crushed and administered via a 
small spoon, in a few milliliters of water or breast milk 
(1 ∣ ⊕ ⊕ ⚪ ).  
 • Brand rather than generic L-T 4 tablets should be used, 
particularly during infancy and in severe cases 
(2 ∣ ⊕ ⊕ ⚪ ).  
 • L-T 4 liquid should only be used if pharmaceutically 
produced (1 ∣ ⊕ ⊕ ⚪ ). 
 • Parents should be provided with written instructions 
on L-T 4 treatment (1 ∣ ⊕ ⚪ ⚪ ). 
 3.2 Monitoring of dose and follow-up  
 • Serum or plasma FT4 (or TT4) and TSH concentra-
tions should be determined at least 4 h after the last 
L-T 4 administration (1 ∣ ⊕ ⊕ ⚪ ).  
 • TSH concentration should be maintained in the age-
specific reference range; TT 4 or FT4 concentration 
should be maintained in the upper half of the age-spe-
cific reference range (1 ∣ ⊕ ⊕ ⚪ ).  
 • Any reduction of L-T 4 dose should not be based on a 
single increase in FT4 concentration during treatment 
(1 ∣ ⊕ ⊕ ⚪ ).  
 • The first follow-up examination should take place 1–2 
weeks after the start of L-T 4 treatment (1 ∣ ⊕ ⚪ ⚪ ).  
 • Subsequent evaluation should take place every 2 weeks 
until a complete normalization of TSH concentration 
is reached; then every 1 to 3 months thereafter until the 
age of 12 months (1 ∣ ⊕ ⚪ ⚪ ). Between the ages of one 
and three years, children should undergo frequent 
clinical and laboratory evaluations (every 2 to 4 
months) (1 ∣ ⊕ ⚪ ⚪ ). Thereafter, evaluations should be 
carried out every 3 to 12 months until growth is com-
pleted (1 ∣ ⊕ ⚪ ⚪ ).  
 • More frequent evaluations should be carried out if 
compliance is questioned or abnormal values are ob-
tained (1 ∣ ⊕ ⚪ ⚪ ).  
 • Additional evaluations should be carried out 4–6 weeks 
after any change in L-T 4 dose or formulation (1 ∣ ⊕ ⚪ ⚪ ). 
 • Adequate treatment throughout childhood is essential 
and overtreatment should be avoided (1 ∣ ⊕ ⊕ ⊕ ).  
 3.3 Thyroid re-evaluation  
 • Re-evaluation of the thyroid axis is indicated when no 
diagnostic assessment was carried out in infancy, and 
particularly when the infant was preterm/sick at the 
time of referral (1 ∣ ⊕ ⊕ ⊕ ).  
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 • For a precise diagnosis, L-T 4 treatment should be 
phased out over a 4- to 6-week period, and a full re-
evaluation should be carried out, with both biochemi-
cal testing and thyroid imaging if hypothyroidism is 
confirmed (2 ∣ ⊕ ⊕ ⚪ ).  
 • If the presence or absence of primary CH is being 
assessed, rather than an exact diagnosis being 
sought, re-evaluation may be carried out by decreas-
ing the dose of L-T 4 by 30% for 2–3 weeks and
then rechecking thyroid function. If an increase in 
TSH concentrations to  ≥ 10 mU/l is demonstrated, 
CH is confirmed. Otherwise the dose can be reduced 
further, with retesting after another 2–3 weeks. 
(2 ∣ ⊕ ⊕ ⚪ ).  
 3.4 Treatment and monitoring in pregnant women 
with CH  
 • We recommend an immediate increase in L-T4 dose 
by 25–30% following a missed menstrual cycle or pos-
itive home pregnancy test (1 ∣ ⊕ ⚪ ⚪ ).  
 • TSH and FT4 (or total T 4 [TT4]) levels should be mon-
itored every 4–6 weeks during the pregnancy, aiming 
at TSH concentrations <2.5 mU/l in the first trimester 
and <3 mU/l later in pregnancy (1 ∣ ⊕ ⚪ ⚪ ).  
 4.1 Outcomes in treated patients  
 • Psychomotor development and school progression 
should be monitored and recorded in all children with 
CH, and particularly in at-risk cases (absent knee 
epiphyses at term, very low TT 4 or FT4, and very high 
TSH concentrations at diagnosis, athyreosis, delayed 
normalization of TSH, poor control during the first 
year, delayed milestones) (1 ∣ ⊕ ⊕ ⊕ ).  
 • A personalized educational plan is required if school 
progress is affected in cases of severe CH (2 ∣ ⊕ ⊕ ⚪ ).  
 • Concerns about behavior should be addressed from 
the time of diagnosis until school age (2 ∣ ⊕ ⊕ ⚪ ).  
 • Memory deficits may be corrected by targeted training 
(2 ∣ ⊕ ⊕ ⚪ ).  
 • Repeated (not just neonatal) hearing tests should be 
carried out before school age and, as required 
(2 ∣ ⊕ ⊕ ⚪ ).  
 • We recommend assessment for evidence of visual pro-
cessing problems (not just visual acuity) (2 ∣ ⊕ ⚪ ⚪ ).  
 • We recommend screening for speech delay and refer-
ral for speech therapy by 3 years if required (2 ∣ ⊕ ⊕ ⚪ ). 
 4.2 Health-related quality of life (HrQOL)  
 • Compliance with treatment should be promoted 
throughout life (1 ∣ ⊕ ⊕ ⊕ ).  
 • There is a risk of subtle decrease in HrQOL in young 
adulthood, particularly if treatment is suboptimal 
(2 ∣ ⊕ ⚪ ⚪ ).  
 4.3 Patient education and compliance/adherence  
 • Medical education about CH should be improved at all 
levels, with regular updates (1 ∣ ⊕ ⊕ ⊕ ).  
 • The education of both parents and patients is essential 
particularly during transition to adult care and during 
pregnancy (1 ∣ ⊕ ⊕ ⊕ ).  
 4.4 Growth, puberty, and fertility  
 • Adherence to treatment influences growth and should 
be promoted (1 ∣ ⊕ ⊕ ⊕ ).  
 • Normal growth, puberty, and fertility can be antici-
pated, if adherence is reasonably good (1 ∣ ⊕ ⊕ ⊕ ).  
 4.5 Bone health  
 • Patients with CH should be adequately treated with thy-
roxine, consume 800–1200 mg of calcium daily, and re-
ceive supplements added if intake is insufficient (2 ∣ ⊕ ⚪ ⚪ ). 
 4.6 Metabolic and cardiovascular health  
 • We recommend lifestyle interventions, including diet 
and exercise, to optimize weight and health in indi-
viduals with CH (2 ∣ ⊕ ⚪ ⚪ ).  
 5.1 Criteria for genetic counselling  
 • Genetic counseling should involve explaining the risk 
of recurrence of CH in an affected family, based on 
family history and thyroid morphology (1 ∣ ⊕ ⊕ ⚪ ).  
 • Each family with an affected child should have access 
to information about the two major forms of CH (dys-
genesis and dyshormonogenesis) and should if possi-
ble receive an explanation of their inheritance and re-
currence rate (1 ∣ ⊕ ⊕ ⚪ ).  
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 • Genetic counseling should be targeted rather than 
general (2 ∣ ⊕ ⊕ ⚪ ).  
 5.2 Molecular biology in the diagnosis and 
management of CH  
 • Molecular genetic study should be preceded by
a careful phenotypic description of CH patients
(including morphology of the thyroid gland) 
(1 ∣ ⊕ ⊕ ⚪ ).  
 • Any syndromic association should be studied genet-
ically, to identify new CH genes and to make it
possible to provide appropriate genetic counseling 
(1 ∣ ⊕ ⊕ ⚪ ).  
 • The presence of familial cases of dysgenesis in siblings 
or parents should lead to a search for TSH receptor or 
PAX8 mutations, respectively (2 ∣ ⊕ ⊕ ⚪ ).  
 5.3 Antenatal diagnosis, screening, and potential 
treatment of fetal CH  
 • We recommend antenatal diagnosis when goiter is 
fortuitously discovered during fetal ultrasound, with a 
family history of dyshormonogenesis and with known 
defects of genes involved in thyroid function or devel-
opment (1 ∣ ⊕ ⊕ ⚪ ).  
 • The therapeutic management of affected fetuses should 
comply with the laws of the country concerned 
(1 ∣ ⊕ ⊕ ⚪ ).  
 • Cordocentesis, rather than amniocentesis, should be 
the reference method for assessing fetal thyroid func-
tion but only performed if prenatal intervention is 
considered (1 ∣ ⊕ ⊕ ⊕ ).  
 • In a euthyroid pregnant woman, a large goiter in the 
fetus with progressive hydramnios and a risk of pre-
mature labor and delivery and/or concerns about tra-
cheal occlusion are criteria in favor of fetal treatment 
in utero (1 ∣ ⊕ ⊕ ⚪ ).  
 • Interventions such as intra-amniotic L-T4 injection 
should be performed only by multidisciplinary spe-
cialist teams (1 ∣ ⊕ ⊕ ⊕ ).  
 Conclusion 
 Further research is required to improve our under-
standing of the pathophysiology and management of this 
heterogenous disorder. 
 Introduction 
 Thyroid hormones play a crucial role in early neuro-
development so that untreated severe CH results in neu-
rological and psychiatric deficits, including intellectual 
disability, spasticity, and disturbances of gait and co-or-
dination. CH is one of the most common preventable 
causes of mental retardation. Screening programs, 
which have been in operation over the last 30 years in 
most industrialized countries, have led to the successful 
early detection and treatment of infants with CH and 
have eliminated the severe neurodevelopmental deficits 
resulting from late diagnosis. Studies on cognitive func-
tion in patients with CH treated soon after birth have 
shown that normal development can be achieved in 
most patients, although some may have subtle neuro-
cognitive deficits  [1] . 
 Estimates of the prevalence of CH vary according to 
the method of ascertainment: about 1 in 2000 to 3000 
live births in countries with neonatal screening vs. about 
1 in 6700 live births before the screening era  [1] . Recent 
reports have indicated that the incidence of primary CH 
may be increasing in some countries, particularly for 
cases with a normally located (eutopic) thyroid gland 
and milder dysfunction. The reasons for this remain un-
clear  [2] but may relate to changes in screening thresh-
olds  [3, 4] . 
 The results from neonatal screening programs have 
also helped to identify a broad spectrum of thyroid dys-
functions with different underlying etiologies. CH can 
be classified according to site: primary (thyroid) or sec-
ondary/central (pituitary and/or hypothalamic); to se-
verity: FT4 levels within the normal range for age 
(compensated) or subnormal (decompensated); and to 
age of onset. The most common form of CH is primary 
hypothyroidism, with high TSH levels reflecting vari-
ous types of abnormal thyroid gland development or 
dyshormonogenesis. Secondary hypothyroidism is 
much less frequent, either with isolated TSH deficiency 
due to mutations inactivating the TSH β-subunit, the 
TRH receptor, or IGSF1 (ImmunoGlobulin Super-
Family member 1), or more commonly with TSH defi-
ciency associated with other pituitary hormone defi-
ciencies. 
 Impaired thyroid hormone production may also be 
temporary or permanent, the latter requiring lifelong 
treatment, and thyroid dysfunction may change in a giv-
en individual with growth and development stages  [5] . 
Transient primary CH can be defined as an increase in 
TSH levels during the neonatal period, with normal TFT 
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results obtained off treatment at a later stage. The purely 
descriptive term ‘hyperthyrotropinemia’ refers to a form 
of compensated CH in which there is a mild increase in 
TSH concentration (eg, 6–20 mU/l) with normal thyroid 
hormone concentrations. It may also be transient or per-
manent. 
 Method for Developing Evidence-Based 
Recommendations  
 Given the importance of optimal screening, prompt 
diagnosis, and adequate treatment of CH, and in recog-
nition of the considerable variations in its management 
worldwide, and the stated need for a consensus-building 
conference  [6] , the European Society for Paediatric En-
docrinology (ESPE) decided to examine current best 
practice in CH and to formulate evidence-based recom-
mendations. This was done by convening a panel of ex-
perts from the ESPE for a consensus conference on CH 
and also by inviting participation from members of the 
following societies: the Pediatric Endocrine Society 
[North America] (PES); the Asia Pacific Paediatric En-
docrine Society (APPES); the Japanese Society for Pedi-
atric Endocrinology (JSPE); the Sociedad Latino-Ameri-
cana de Endocrinología Pediátrica (SLEP); the Austral-
asian Paediatric Endocrine Group (APEG); and the 
Indian Society for Pediatric and Adolescent Endocrinol-
ogy (ISPAE). 
 The target audience for these guidelines includes gen-
eral and specialist pediatricians, other professionals pro-
viding care for patients with CH, and policy makers, par-
ticularly in countries with developing economies current-
ly in the process of initiating neonatal screening programs 
for CH. 
 Participants included individuals from Europe, 
North America (United States and Canada), Latin 
America, Asia, and Australia, with a balanced spectrum 
of professional seniority and expertise. In addition, an 
expert on the development of evidence-based guide-
lines was recruited to serve in an advisory capacity. 
Panel members declared whether they had any poten-
tial conflict of interest at the initial meeting of the 
group. 
 Thirty-two participants were assigned to one of five 
groups to which topics 1–5 were allocated, and a chair-
person was designated for each group. Each participant 
prepared a summary of the literature relating to a par-
ticular question distributed before the conference (which 
was held over 2 days in November 2011). Each group re-
vised the summaries, which were then presented to the 
full conference. This report is based on the questions ad-
dressed. 
 A detailed description of the grading scheme has been 
published elsewhere  [7] . Recommendations were based 
on published findings and on expert opinion when ap-
propriate. The best available research evidence was used 
to develop recommendations. Preference was given to ar-
ticles written in English, identified by PubMed searches 
with MeSH terms. 
 For each point, recommendations and evidence are 
described, with a modification in the grading evidence 
as follows: 1 = strong recommendation (applies to most 
patients in most circumstances, benefits clearly out-
weigh the risk); and 2 = weak recommendation (con-
sensus opinion of working group or should be consid-
ered; the best action may depend on circumstances or 
patient values, benefits, and risks closely balanced or 
uncertain). 
 Qualify of evidence is indicated as follows:  ⊕ ⊕ ⊕ , 
high quality (prospective cohort studies or randomized 
controlled trials at low risk of bias);  ⊕ ⊕ ⚪ , moderate 
quality (observational studies or trials with methodolog-
ical flaws, inconsistent or indirect evidence); and  ⊕ ⚪ ⚪ , 
low quality (case series or nonsystematic clinical obser-
vations). 
 1.0 Neonatal Screening  
 1.1 The benefits of CH screening  
 Recommendations 
 1.1.1 Neonatal screening programs for CH have been 
highly successful and economically beneficial over the 
last four decades. Affected children are detected very 
soon after birth, mostly before clinical symptoms and 
signs become evident. Early detection and treatment pre-
vent morbidity, particularly neurodevelopmental disabil-
ities (1 ∣ ⊕ ⊕ ⊕ ). 
 1.1.1 Evidence  
 Many studies have confirmed the early success of CH 
screening for normalizing the cognitive outcomes of chil-
dren with severe primary CH  [8, 9] , and the timing of the 
normalization of thyroid function may influence the out-
come  [10] . The avoided lifetime costs of care for children 
in whom intellectual disability is prevented as a result of 
screening for CH have been estimated to exceed the costs 
of screening and diagnosis by a large margin  [11] . 
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 1.2 Analytical methodology, effectiveness, and 
efficacy of CH screening strategies  
 Recommendations  
 1.2.1 Screening for primary CH worldwide should be 
performed wherever possible on the basis of national re-
sources. For new programs, there is a need to decide on 
the scope of screening to define the strategy for selecting 
neonatal screening tests. The goal of neonatal screening 
should be to detect all forms of primary CH – mild, mod-
erate, and severe – but particularly those patients with 
severe CH in whom morbidity is high. The most sensitive 
test for detecting primary CH is the determination of 
TSH concentration (1 ∣ ⊕ ⊕ ⊕ ). 
 1.2.2 Primary CH screening has been shown to be ef-
fective for the testing of cord blood or blood collected after 
the age of 24 hours, although the best ‘window’ for testing 
is 48 to 72 hours of age. Blood is spotted onto filter paper, 
allowed to dry, and eluted into a buffer for TSH analysis. 
This method detects primary CH more effectively than 
primary T 4 screening. Primary T 4 screening with confir-
matory TSH testing entails a risk of missing some cases of 
mild forms of primary CH but can detect some cases of 
central CH (CCH). Screening strategies for the detection 
of CCH are based on two approaches: (1) a combination 
of primary T 4 and primary TSH screening; and (2) a com-
bination of primary T 4 screening with secondary TSH 
testing followed by T 4 binding protein determination. The 
inclusion of T 4 binding protein determinations decreases 
the number of false positives. The criteria defining a posi-
tive result must be adapted to the target disease definition 
and the resources of the screening program (1 ∣ ⊕ ⊕ ⊕ ). 
 1.2.1–1.2.2 Evidence  
 The most convincing justification for expanding neo-
natal screening for CH to every country in the world is that 
this approach is the most effective way of preventing men-
tal retardation and ensuring normal IQ in this patient pop-
ulation  [12, 13] . Furthermore, because iodine deficiency is 
the most common preventable cause of mental retarda-
tion, developmental disabilities, and CH worldwide  [8, 14, 
15] , neonatal screening for CH can be used as a sensitive 
indicator of neonatal and maternal iodine nutritional sta-
tus  [16] . The strategy for selecting neonatal screening tests 
focuses on detecting the more severe forms of CH as early 
as possible because disability due to primary CH is greatest 
in patients not treated before the age of 3 months  [8, 17] . 
TSH screening is the most sensitive test for primary CH 
detection and should be the single most important test in 
any screening program  [8, 17, 18] . Predictably, an increase 
in the reported incidence of primary CH occurs when cut-
off levels for TSH are lowered  [3, 12, 17, 19, 20] . Studies on 
long-term outcome are required to determine whether 
there is a risk of permanent disability in these milder cases 
with only moderate TSH elevation and normal T 4 levels 
and whether these individuals have permanent or transient 
thyroid dysfunction  [6] . 
 There is some published evidence to suggest that neo-
natal screening for CCH may also fulfil criteria for disease 
screening  [21–24] : (1) CCH is a relatively frequent dis-
ease with an incidence similar to that of phenylketonuria 
in some populations; (2) screening tests are available and 
inexpensive; (3) treatment is available and effective; and 
4) the risks of an unfavorable outcome in cases of delayed 
diagnosis are well known, although outcome studies 
showing that screening is superior to detection through 
clinical presentation are lacking  [22] .
 1.3 Screening in special categories of neonates at 
risk of CH  
 Recommendations  
 1.3.1 Specific biochemical criteria should be used for 
screening special categories of neonates at risk of transient 
and permanent CH and in whom initial screening tests 
may be inappropriate or provide normal results. A strat-
egy of second screening may be required in the following 
conditions: preterm neonates with a gestational age (GA) 
of less than 37 weeks; LBW and VLBW neonates; ill and 
preterm neonates admitted to NICU; specimen collection 
within the first 24 hours of life; and multiple births, par-
ticularly in cases of same-sex twins. The repeat specimen 
should be collected at about 2 weeks of age, or 2 weeks af-
ter the first screening test was carried out. The interpreta-
tion of screening results should take into account the re-
sults of all specimens analyzed in a multiple sampling 
strategy. The criteria defining a positive screening test re-
sult should be adapted for the analytical parameters mea-
sured, the method used, and the age at sampling and ma-
turity (GA/birth weight) of the infant (2 ∣ ⊕ ⊕ ⚪ ). 
 1.3.1 Evidence  
 Several studies have generated data that argue for mul-
tiple sampling in preterm neonates with a GA of less than 
37 weeks, LBW and very LBW neonates, ill and preterm 
neonates admitted to NICU, infants from whom a speci-
men is collected within the first 24 hours of life, and neo-
nates from multiple births, particularly in case of mono-
zygotic twins  [8, 9, 12, 17, 19, 25–29] . This approach re-
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flects concern that primary CH may be masked in these 
situations due to the suppression of TSH caused by drug 
administration  [30, 31] , by hypothalamic-pituitary im-
maturity  [32] , by fetal blood mixing in multiple births 
[33], and by other effects of serious neonatal illnesses  [34–
36] . Thus, it is the policy in many centers to remeasure 
dried blood spot (DBS) TSH in at-risk infants as they ap-
proach discharge from hospital. Repeat screening has not 
been adopted by all screening programs, some centers ar-
guing that the limited data available suggest that, although 
it has identified neonates with delayed rise in TSH, this is 
mostly a transient problem  [27] . Further outcome data 
from this complex population of newborn infants are 
needed to better inform clinical practice. 
 Some neonatal screening programs test for T 4 alone in 
the initial screen, whereas TSH may also be assessed on the 
first specimen. However, most programs initially assessing 
T 4 only subsequently evaluate TSH concentration for the 
neonates with the lowest T 4 values (usually the lowest 10% 
of the T 4 values for the day). If TSH concentration is high, 
the infant is recalled for evaluation and testing. Repeat DBS 
specimens are collected if the T 4 value is below a defined 
cutoff value for GA  [37, 38] . If the TSH test result in the ini-
tial screening was normal, but repeat testing shows TSH 
concentration to be high, the evaluation and possible treat-
ment of transient (in most cases) or permanent primary CH 
should be initiated promptly. Neonates with a persistently 
low T 4 concentration in DBS tests should have serum FT4 
and TSH determinations to confirm or exclude CCH  [8, 9] . 
 2.0 Criteria for Diagnosis  
 2.1 Biochemical criteria for use in the decision to 
initiate treatment in an infant with high TSH and/or 
low FT4 concentration  
 Recommendations  
 2.1.1 We recommend starting treatment immediately 
after baseline serum TSH and FT4 determination if DBS 
TSH concentration is  ≥ 40 mU/l of whole blood. If DBS 
TSH concentration is <40 mU/l of whole blood, the clini-
cian may postpone treatment, pending the serum results, 
for 1–2 days (1 ∣ ⊕ ⊕ ⚪ ).
 2.1.2 We recommend starting treatment immediately 
if serum FT4 concentration is below the norm for age, 
regardless of TSH concentration (1 ∣ ⊕ ⊕ ⊕ ). 
 2.1.3 We suggest that treatment should be started if 
venous TSH concentration is persistently >20 mU/l, even 
if serum FT4 concentration is normal (2 ∣ ⊕ ⚪ ⚪ ). 
 2.1.4 When venous TSH concentration is between 6 
and 20 mU/l in a well baby with an FT4 concentration 
within the normal limits for age, we suggest diagnostic 
imaging to try to establish a definitive diagnosis (2 ∣ ⊕ ⚪ ⚪ ). 
If TSH concentration remains high for more than 3 to 4 
weeks, we suggest (in discussion with the family) either 
starting L-T 4 supplementation immediately and retest-
ing, off treatment, at a later stage; or retesting 2 weeks 
later without treatment (2 ∣ ⊕ ⚪ ⚪ ). 
 2.1.1–2.1.4 Evidence  
 L-T 4 treatment must be started immediately if venous 
FT 4 or TT4 levels are low, given the known adverse effect 
of untreated decompensated CH on somatic growth and 
neurodevelopment  [39] . Previous work has shown that 
the likelihood of decompensated hypothyroidism is high 
if DBS TSH values are above 40 mU/l  [40] , justifying im-
mediate treatment if DBS TSH concentration is above 
this value. Given that the period between birth and the 
age of 3 years is a critical time for neurocognitive develop-
ment, most clinicians would advocate treatment when 
TSH concentration is >20 mU/l, carefully monitoring 
thyroid function to avoid overtreatment, and retesting af-
ter 3 years if the thyroid is normally located  [41] . Manage-
ment remains a matter of debate for cases in which TSH 
concentrations are high, but to a lesser extent (6–20 
mU/l), and FT4 levels are normal  [42] . The family should 
be informed that this is a ‘gray area’ but that many clini-
cians would advise ‘playing safe’ and treating during ear-
ly childhood in this situation  [43] . 
 2.2 Communication of high TSH concentration 
results on neonatal screening to the family, the 
family doctor, and the local pediatrician  
 Recommendations 
Communicating the initially high capillary TSH 
concentration result  
 2.2.1 The detection of a high TSH concentration on 
screening should be communicated by an experienced 
person (2 ∣ ⊕ ⚪ ⚪ ), such as a member of the screening lab-
oratory staff or one of the pediatric endocrine team. 
 2.2.2 The high TSH concentration should be commu-
nicated to the family either by telephone or in person as 
soon as possible (2 ∣ ⊕ ⚪ ⚪ ). 
 2.2.3 Communication may be directly with the family 
or via the family doctor, health visitor, or midwife 
(2 ∣ ⊕ ⚪ ⚪ ). 
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 Seeing the baby for clinical examination, 
investigation, and treatment  
 2.2.4 If possible, the baby should be seen for clinical 
assessment and venous thyroid function testing on the 
day of referral or on the next day at the latest (1 ∣ ⊕ ⚪ ⚪ ). 
 2.2.5 Centers should have relevant information
materials about the diagnosis and management of CH 
in the appropriate languages for their community 
(2 ∣ ⊕ ⚪ ⚪ ). 
 2.2.6 The parents should be shown how to give the first 
dose of L-T 4 , by either the clinician or the pharmacist 
(2 ∣ ⊕ ⚪ ⚪ ). 
 Communication with the family doctor, local 
pediatrician, and educators  
 2.2.7 The baby’s family doctor and local pediatrician 
should be notified either by telephone or by letter to
outline the provisional diagnosis and management 
(1 ∣ ⊕ ⚪ ⚪ ). 
 2.2.8 Options regarding shared care should be dis-
cussed with the clinician at the local level (1 ∣ ⊕ ⚪ ⚪ ). 
 2.2.9 When the child reaches nursery or school age, the 
consensus group advises against informing educators and 
teachers about the child having CH, to prevent ‘labeling’ 
and stigmatization (2 ∣ ⊕ ⊕ ⚪ ). 
 2.2.1–2.2.9 Evidence  
 ESPE guidelines provide little information about 
contacting and counseling the families of neonates with 
high TSH concentrations  [44] . A survey of British pe-
diatricians in 2006/2007 indicated that 54 of the 119 pe-
diatricians questioned (43%) would always see the in-
fant on the day of notification, whereas 65 (55%) would 
usually see the baby a day or so later  [45] . Age at treat-
ment initiation during the first month of age was not 
shown to be a factor in educational attainment in a large 
French cohort study  [46] , but there are common sense 
grounds for starting L-T 4 treatment as soon as possible 
after birth to prevent irreversible neurocognitive im-
pairment. 
 2.3 Criteria for assessing CH severity in terms of 
clinical, biochemical, and radiological features  
 Recommendations  
 2.3.1 CH severity can be assessed clinically – on the 
basis of symptomatic hypothyroidism; biologically – as 
severe, moderate, or mild on the basis of serum FT4 levels 
of <5, 5 to <10, and 10 to 15 pmol/l, respectively; on the 
basis of delayed epiphyseal maturation on knee x-ray; and 
in terms of the etiology of CH (1 ∣ ⊕ ⊕ ⊕ ). 
 A serum thyroglobulin concentration below the detec-
tion threshold is highly suggestive of athyreosis or a com-
plete thyroglobulin synthesis defect (2 ∣ ⊕ ⊕ ⊕ ). 
 2.3.1 Evidence  
 The clinical symptoms and signs of symptomatic CH 
include sleepiness, not waking for feeds, poor and slow 
feeding, cold extremities, prolonged neonatal jaundice, 
lethargy, hypotonia, macroglossia, umbilical hernia, and 
dry skin with or without a coarse/puffy face. Persistence 
of the posterior fontanelle, a large anterior fontanelle, and 
a wide sagittal suture all reflect delayed bone maturation, 
which can be further documented by knee x-ray. The ab-
sence of one or both knee epiphyses has been shown to be 
related to: (1) T 4 concentration at diagnosis; and (2) IQ 
outcome, and is thus a reliable index of intrauterine hy-
pothyroidism  [47, 48] . A threshold effect of subnormal 
TT4 concentration on IQ has also been claimed, with a 
10-point IQ difference between children with initial TT4 
concentrations below 40 nmol/l (equivalent to 5.5 pmol/l 
of FT4) and children with normal TT4 concentrations 
 [49] . Data for 82 10-day-old neonates yielded 2.5th per-
centile, median, and 97.5th percentile values of 1.18, 1.75, 
and 2.49 ng/dl – equivalent to 15.2, 22.5, and 32 pmol/l 
 [50] – making it possible to construct a scale of biochem-
ical severity on the basis of plasma FT4 concentrations of 
<5, 5 to <10, and 10 to 15 pmol/l. Imaging may reveal se-
vere primary CH in cases of absence/severe hypoplasia of 
the gland or of complete organification defect with goiter. 
Alternatively, imaging may show various degrees of se-
verity in cases of ectopic gland or normally shaped and 
located gland. A pragmatic conclusion as to the severity 
of CH can therefore be made when the clinical history, 
physical findings, initial venous blood biochemistry re-
sults, and knee x-ray and thyroid imaging results (if avail-
able) are considered together. 
 2.4 The place of imaging techniques – scintigraphy 
with or without perchlorate discharge test and 
ultrasonography – in the diagnosis of CH  
 Recommendations  
 2.4.1 We recommend performing imaging studies to 
determine the specific etiology (1 ∣ ⊕ ⊕ ⚪ ). 
 2.4.2 Both scintigraphy and ultrasound should be con-
sidered in neonates with high TSH concentrations 
(2 ∣ ⊕ ⊕ ⚪ ). 
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 2.4.3 Imaging should never be allowed to delay the ini-
tiation of treatment. Scintigraphy should be carried out 
within 7 days of starting L-T 4 treatment (1 ∣ ⊕ ⊕ ⚪ ). 
 2.4.4 Infants found to have a normal-sized gland in 
situ in the absence of a clear diagnosis should undergo 
further reassessment of the thyroid axis at a later age 
(1 ∣ ⊕ ⚪ ⚪ ). 
 2.4.1–2.4.4 Evidence 
Scintigraphy  
 Scintigraphy may be carried out with either 10–20 
MBq of technetium-99m ( 99m Tc) or 1–2 MBq of io-
dine-123 ( 123 I).  99m Tc is more widely available, less ex-
pensive, and quicker to use than  123 I. However,  123 I is 
specifically taken up by the thyroid gland and gives a 
clearer scan than  99m Tc  [51] . Scintigraphy can identify 
athyreosis (absence of uptake), hypoplasia of a gland in 
situ (with or without hemithyroid), a normal or large 
gland in situ with or without abnormally high levels of 
uptake, and an ectopic thyroid at any point along the 
pathway of the normal embryological descent from the 
foramen caecum at the base of the tongue to the thyroid 
cartilage. An enrichment of the tracer within the salivary 
glands can lead to misinterpretation, especially on lat-
eral views, but this can be avoided by allowing the infant 
to feed before scintigraphy, thus emptying the salivary 
glands. When the thyroid is in the normal position, a 
discharge of >10% of the  123 I dose when perchlorate is 
administered at 2 hours (the perchlorate discharge test) 
indicates an organification defect  [51] . Scintigraphy 
may show no uptake despite the presence of a eutopic 
thyroid gland with excess iodine intake through expo-
sure (eg, from antiseptic preparations), maternal TSH 
receptor blocking antibodies, TSH suppression from 
L-T 4 treatment, and inactivating mutations in the TSH 
receptor and the sodium/iodide symporter (NIS)  [52, 
53] .
 Ultrasound  
 The thyroid gland is a superficial structure that can be 
imaged by ultrasonography with a high-frequency linear 
array transducer (10–15 MHz) at a resolution of 0.7 to 1.0 
mm. Ultrasound imaging, performed in the longitudinal 
and axial planes, can be used to investigate the absence or 
presence, size, echogenic texture, and structure of a thy-
roid gland in situ. However, it cannot always detect lin-
gual and sublingual thyroid ectopy  [54–56] , although the 
use of color Doppler facilitates the identification of thy-
roid tissue by demonstrating marked increases in blood 
flow  [57] . Ultrasonography is highly observer-depen-
dent, and investigators should be particularly wary of 
misdiagnosing nonthyroidal tissue in the thyroid fossa as 
a dysplastic thyroid gland in situ  [54, 58] . Thyroid tissue 
is more echogenic than muscle but less echogenic than 
fat. In the absence of thyroid tissue in the normal location, 
small hyperechoic structures of approximately the same 
echogenicity as fat are found laterally on both sides of the 
trachea, mimicking the appearance of a thyroid gland. 
Cysts have also been described within the empty thyroid 
area  [59] . 
 Scintigraphy and ultrasound combined  
 Combining scintigraphy and thyroid ultrasound in the 
individual patient helps to: (1) improve diagnostic accu-
racy  [55, 60] ; (2) identify a eutopic gland, which may be 
normal, enlarged, or hypoplastic, thus guiding further di-
agnostic investigations, including molecular genetics 
studies; (3) prevent the incorrect diagnosis of athyreosis 
in the context of an absence of uptake on scintigraphy 
when ultrasound shows a normal gland in situ; and (4) 
detect thyroid ectopy reliably.  Table 1  shows the diagnos-
tic patterns to be found in thyroid dysgenesis, dyshor-
monogenesis, and some forms of transient CH when ul-
trasound, scintigraphy, and serum thyroglobulin mea-
surement are combined.
 2.5. Congenital malformations and syndromes
that should be systematically sought for in infants 
with CH  
 Recommendations  
 2.5.1 A thorough physical examination should be car-
ried out in all neonates with high TSH concentrations for 
the detection of congenital malformations, particularly 
those affecting the heart, and in children for the identifi-
cation of any underlying dysmorphic syndrome or neu-
rodevelopmental disorders (1 ∣ ⊕ ⊕ ⊕ ). 
 2.5.1 Evidence  
 The prevalence of congenital malformations, particu-
larly cardiac malformations, including septal defects, re-
nal abnormalities, and the risk of neurodevelopmental 
disorders is higher in subjects with CH than in the gen-
eral population  [61–65] . However, care must be taken to 
distinguish between true CH and transient increases in 
TSH concentration in sick infants with and without ex-
trathyroidal malformations, including heart and great 
vessel defects such as patent ductus arteriosus  [66] . There 
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is no good evidence to suggest that additional screening 
measures, other than careful clinical examination, are re-
quired for detecting extrathyroidal malformations or co-
morbidities. 
 Down syndrome is associated with a mild increase in 
TSH concentration from the neonatal period onward, 
although it is usually too small for detection by neonatal 
screening, as well as a shift to the left of the FT4 distribu-
tion so that mean values are lower when compared with 
the general population  [67] . Pendred syndrome, with or 
without goiter, and pseudohypoparathyroidism may 
both present with mild or moderate increases in TSH 
concentration during the neonatal period and should be 
included in the differential diagnosis of CH with gland 
in situ  [60] . 
 3.0 Treatment and Monitoring of CH  
 3.1 Initial treatment and therapeutic regimens  
 Recommendations  
 3.1.1 L-T 4 alone is recommended as the treatment of 
choice for CH (1 ∣ ⊕ ⊕ ⚪ ). 
 3.1.2 Treatment with L-T 4 should be started as soon as 
possible, and no later than the first 2 weeks of life
or immediately after confirmatory serum test results in 
infants identified in a second routine screening test. We 
recommend an initial L-T 4 dose of 10 to 15 μg/kg per day. 
Infants with severe disease, as defined by a very
low pretreatment TT 4 or FT4 concentration, should be 
treated with the highest initial dose, and those with a mild 
to moderate hypothyroidism with a lower dose (1 ∣ ⊕ ⊕ ⚪ ). 
Table 1.  Thyroid ultrasound, scintigraphy, and serum thyroglobulin findings in thyroid dysgenesis, dyshormonogenesis, and some forms 
of transient CH
Defect Thyroid ultrasound Thyroid scintigraphy Serum thyroglobulin 
concentration 
Thyroid dysgenesis
Apparent athyreosis No thyroid tissue seen No uptake Detectable (≥2 μg/l)
True athyreosis No thyroid tissue seen No uptake Undetectable
Ectopy Either no thyroid tissue seen 
or ectopic tissue seen 
(especially if in a sublingual 
or perihyoid location)
Uptake into ectopic gland Usually ↑ but may be 
N or ↓
Hypoplasia in situ Small eutopic gland Low level of uptake in a normally 
sited gland
N or ↓
Hemiagenesis Hemithyroid Hemithyroid N
Dyshormonogenesis
NIS/SCL5A5 Enlarged gland Uptake absent or ↓↓ ↑
Thyroid peroxidase, TPO Enlarged gland High level of uptake; positive 
perchlorate discharge test
↑↑
Dual oxidase 2, DUOX2/dual oxidase 
2 maturation factor, DUOXA2
Enlarged gland High level of uptake; positive 
perchlorate discharge test
↑
Thyroglobulin, TG Enlarged gland Avid uptake; normal perchlorate 
discharge test
↓↓ or undetectable 
Pendred syndrome, pendrin PDS/
SCL26A4
Normal/enlarged gland High level of uptake; positive 
perchlorate discharge test
↑
Dehalogenase, IYD/DEHAL1 Enlarged gland Avid uptake; normal perchlorate 
discharge test
↑
Transient CH
Acute iodine excess Normal gland in situ No uptake N or ↓
Chronic iodine deficiency Large gland Avid uptake ↑
Maternal blocking antibodies N or small gland Uptake ↓ or absent N or ↓
TSH receptor N or small gland Uptake ↓ or absent N or ↓
 N = Normal.
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 3.1.3 L-T 4 should be administered orally. If oral ad-
ministration is not possible, it can also be administered 
iv, in which case the iv dose should be no more than 80% 
the oral dose. The dose should then be adjusted according 
to TSH and FT4 determinations (1 ∣ ⊕ ⊕ ⚪ ). 
 3.1.4 We recommend the administration of L-T 4 in 
tablet form. In neonates and infants, the tablets can be 
crushed and administered via a small spoon, with suspen-
sion, if necessary, in a few milliliters of water or breast 
milk. L-T 4 can also be administered in liquid form, but 
only if pharmaceutically produced and licensed L-T 4 so-
lutions are available (1 ∣ ⊕ ⊕ ⚪ ). A brand rather than a ge-
neric formulation is recommended in CH, at least in in-
fancy (2 ∣ ⊕ ⊕ ⚪ ). 
 3.1.5 L-T 4 can be administered or taken in the morning 
or evening, either before feeding or with food, but it 
should be administered in the same way every day. The 
dose should then be adjusted according to TSH and FT4 
determinations to establish the appropriate dose in each 
setting. Caution should be taken with the administration 
of vitamin D during the first weeks of life, and the intake 
of soy, iron, and calcium at the time of L-T 4 administra-
tion should be avoided (1 ∣ ⊕ ⊕ ⊕ ). 
 3.1.6 Parents should be provided with written instruc-
tions on L-T 4 treatment to avoid uncertainties that might 
hinder compliance (1 ∣ ⊕ ⚪ ⚪ ). 
 3.1.1–3.1.6 Evidence  
 T 3 is the biologically active hormone, but there is 
no evidence that combined therapy with L-T 4 and 
L-T 3 is more beneficial than treatment with L-T 4 alone, 
probably due to the high degree of efficiency of endog-
enous deiodinases, which break T 4 down into T 3  [68, 
69] . L-T 4 is available in tablet form (the most widely 
used form) or as a pharmaceutically produced and li-
censed liquid form. Unlike suspensions prepared by 
pharmacists, this licensed L-T 4 solution allows reliable 
dosing and is a convenient way of administering L-T 4 , 
particularly to infants and young children  [70–73] . 
Recent evidence suggests that brand and generic L-T 4 
are not bioequivalent and that for CH, particularly in 
severe cases, it is prudent to use a brand preparation 
 [74] . 
 The orally administered hormone has a mean bioavail-
ability of 50 to 80%, which may be influenced by the pres-
ence of food (soy) or minerals (calcium, iron). In infants 
with CH, hypersensitivity to vitamin D administration 
with hypercalcemia has been described during the first 
few weeks of L-T 4 treatment, possibly due to the admin-
istration of prophylactic doses of vitamin D  [75, 76] . In 
adults, L-T 4 administration at bedtime seems to be even 
more effective in terms of thyroid hormone levels than 
administration in the morning and is now considered to 
be as effective as morning administration in the fasting 
state  [77] . 
 The early initiation of L-T 4 treatment, within the first 
2 weeks of life, has been shown to be crucial for neurode-
velopment and for the achievement of a normal intellec-
tual outcome in affected children  [78–81] . Disease sever-
ity, as judged by very low initial levels of thyroid hor-
mones due to the absence or loss of function of the thyroid 
gland and by severely delayed bone age, has also been 
shown to be an important predictive factor for neurode-
velopment  [49, 82–87] . Severely affected children may 
benefit from a higher initial dose of L-T 4 , leading to the 
more rapid normalization of thyroid hormone levels and 
potentially resulting in a better intellectual outcome  [88–
91] . 
 3.2 Monitoring of treatment and adverse events
Recommendations  
 3.2.1 The monitoring of L-T 4 treatment should be 
based on periodic measurements of serum or plasma 
FT4 (or TT 4 ) and TSH concentrations. The blood sam-
ples for laboratory evaluation should be collected at 
least 4 hours after the last L-T 4 administration (1 ∣ ⊕ ⊕ ⚪ ). 
We recommend maintaining TSH in the age-specific 
reference range (but to avoid undetectable TSH <0.05 
mU/l) and serum concentrations of TT 4 or FT4 in the 
upper half of the age-specific reference range (1 ∣ ⊕ ⊕ ⚪ ). 
If necessary, the treatment should be adjusted accord-
ing to the hormone concentrations measured, but de-
creases in LT4 dose should not be based on a single high 
FT4 concentration during treatment (1 ∣ ⊕ ⊕ ⚪ ). Clini-
cians should be familiar with the reference ranges for 
the methods used by the laboratory carrying out the 
tests (1 ∣ ⊕ ⚪ ⚪ ). 
 3.2.2 We recommend performing the first follow-up 
examination 1 to 2 weeks after the start of L-T 4 treatment, 
with intense follow-up over the first year of life (every 2 
weeks until TSH levels are completely normalized and ev-
ery 1 to 3 months thereafter, until the age of 12 months). 
Between the ages of 1 and 3 years, children should un-
dergo frequent clinical and laboratory evaluations (every 
2 to 4 months), with regular evaluations every 3 to 12 
months thereafter until growth is completed. Measure-
ments should be performed at more frequent intervals if 
compliance is questioned or abnormal values are ob-
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tained, and 4 to 6 weeks after any change in L-T 4 dose or 
L-T 4 formulation (eg, switch from brand to generic L-T 4 ) 
(1 ∣ ⊕ ⚪ ⚪ ). 
 3.2.3 The incidence of adverse events during L-T 4 
treatment is very low. The careful monitoring of thyroid 
hormone parameters, during both initial and mainte-
nance treatment, is recommended to minimize the risk 
(1 ∣ ⊕ ⚪ ⚪ ). 
 3.2.4 In children with pre-existing cardiac insufficien-
cy, we suggest introducing L-T 4 at 50% of the target re-
placement dose and increasing this in accordance with 
FT4 levels after 2 weeks (2 ∣ ⊕ ⚪ ⚪ ). 
 3.2.1–3.2.4 Evidence  
 The rapid normalization of thyroid hormone levels 
(within the first 2 weeks after treatment initiation) and 
the maintenance of relatively higher FT4 concentrations 
during the first year of life lead to a better intellectual out-
come  [90, 92, 93] . The frequent monitoring of TSH and 
FT4 levels is required for this and also for preventing the 
occurrence of prolonged periods of supraphysiological 
thyroid hormone levels  [94–96] . After adjustment to L-T 4 
dosage, it is appropriate to recheck thyroid function, and 
the recommended interval of 4–6 weeks is in keeping with 
the American Academy of Pediatrics guidelines  [8] . The 
adequate treatment of CH minimizes the risk of treat-
ment-related adverse effects  [97–99] . Based on neurolog-
ical and cardiac complications that have occasionally 
been described (albeit primarily in patients with inade-
quate T 4 treatment), patients with pre-existing health 
conditions or with a very late diagnosis may require spe-
cial attention during treatment  [100, 101] . 
 3.3. Criteria for re-evaluating the thyroid axis, to 
distinguish between permanent CH and transient 
increases in TSH concentration, and for treatment 
withdrawal in children with normally sited gland  
 Criteria for re-evaluation of the thyroid axis 
Recommendations  
 3.3.1 We recommend re-evaluation of the thyroid axis 
in cases in which no etiological diagnostic assessment was 
carried out during early infancy and/or when treatment 
was started in the context of the infant being ill (eg, pre-
term). Re-evaluation is also mandatory when initial evalu-
ation has shown a normally located gland, with or without 
goiter, in neonates with positive thyroid antibodies, in 
children who have required no increase in L-T 4 dose since 
infancy, and in children in whom no enzyme defect has 
been identified, either because no molecular genetic inves-
tigations have been carried out or because investigations 
have proved negative for all mutations tested (1 ∣ ⊕ ⊕ ⚪ ). 
 3.3.2 Retesting off treatment may be waived if venous 
TSH concentration has risen after the first year of life, due 
to either L-T 4 underdosage or poor compliance with 
treatment (1 ∣ ⊕ ⊕ ⚪ ). 
 3.3.3 Re-evaluation of the thyroid axis is not indicated 
when thyroid dysgenesis has been conclusively shown on 
imaging or (with the exception of DUOX.2 mutations or 
Pendred syndrome) when dyshormonogenesis has been 
confirmed by molecular genetic testing (1 ∣ ⊕ ⊕ ⊕ ). 
 3.3.1–3.3.3 Evidence  
 Thyroid re-evaluation is important if no definitive di-
agnosis was made during the neonatal period; it has been 
shown that one-third of patients with CH and normally 
located glands may have transient thyroid dysfunction  [41, 
60] . Re-evaluation is unnecessary if thyroid imaging at the 
time of neonatal screening showed thyroid ectopy, appar-
ent athyreosis, or true athyreosis. However, caution is re-
quired when diagnosing athyreosis on the basis of isotope 
scanning alone because an absence of uptake in the context 
of a gland normally located on ultrasound scan may occur 
with excess iodine exposure, maternal antibodies blocking 
the TSH receptor, or NIS gene defects  [52, 53] .
 Re-evaluation is essential in subjects who were pre-
term or sick during the neonatal period  [27] . Other in-
fants in whom initial evaluation showed a normal/slight-
ly small gland on ultrasound with little or no uptake on 
scintigraphy should also be re-evaluated because this pat-
tern is suggestive of either maternal antibodies blocking 
the TSH receptor or biallelic-TSH receptor mutations 
 [102] . Because iodine deficiency may mimic dyshor-
monogenesis (both conditions display thyroid enlarge-
ment and avid tracer uptake), retesting is indicated in 
children who appear to have mild dyshormonogenesis 
 [103] . Transient CH has also been linked to genetic de-
fects such as heterozygous DUOX2 mutation  [104, 105] .
 Timing of thyroid re-evaluation 
Recommendations  
 3.3.4 Re-evaluation of the thyroid axis, off treatment, 
should normally take place after the age of 3 years 
(1 ∣ ⊕ ⊕ ⚪ ). 
 3.3.5 Earlier re-evaluation may be indicated if the clin-
ical context renders transient increases in TSH concen-
tration highly probable; for example: (1) in the case of 
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newborns in whom thyroid peroxidase or TSH receptor 
antibodies are detectable in the blood; and (2) when a eu-
topic, normally sized gland is found on ultrasound scans 
(2 ∣ ⊕ ⊕ ⚪ ). 
 3.3.4–3.3.5 Evidence  
 Magnetic resonance imaging studies have shown that 
the myelination of the central nervous system is complet-
ed by 36 to 40 months of age  [106] , at which point the 
child is more likely to be co-operative for thyroid imaging 
than at the age of 1 or 2 years. However, if transient in-
creases in TSH concentration are likely, the clinician may 
consider the earlier withdrawal of treatment from 1 year 
of age. 
 Method of thyroid re-evaluation 
Recommendations  
 3.3.6 If a precise diagnosis is sought, L-T 4 should be 
phased out over a 4 to 6-week period (depending on the 
size of the maintenance dose) and a full re-evaluation car-
ried out at the end of this period, with biochemical testing 
and thyroid imaging if hypothyroidism is confirmed 
(2 ∣ ⊕ ⚪ ⚪ ). 
 3.3.7 If the clinician wishes to establish the presence 
or absence of primary hypothyroidism rather than
to obtain an exact diagnosis, L-T 4 dose may be decreased 
by 30% for 2 to 3 weeks. If an increase in TSH concen-
tration to  ≥ 10 mU/l is observed during this period, then 
continuing hypothyroidism can be assumed. By con-
trast, if thyroid function remains normal, the dose may 
be reduced further, followed by retesting (2 ∣ ⊕ ⊕ ⚪ ). 
 3.3.6–3.3.7 Evidence 
 By the age of 2 to 3 years, the severity of thyroid im-
pairment may be evident from a lower dose requirement 
 [41, 103] or, if compliance has been imperfect, high TSH 
levels despite treatment.
 3.4 Treatment and monitoring in pregnant women 
with CH  
 Recommendations  
 3.4.1 For women with CH who are planning a preg-
nancy, even greater efforts should be made to ensure that 
maternal thyroid hormones are optimal. In newly preg-
nant patients, we recommend an immediate increase in 
L-T 4 dose by 25 to 30% after a missed menstrual cycle or 
positive home pregnancy test (1 ∣ ⊕ ⚪ ⚪ ). 
 3.4.2 TSH and FT4 (or TT 4 ) levels should be evaluated 
as soon as pregnancy is confirmed, every 4 to 6 weeks dur-
ing the pregnancy, and 4 weeks after every change in dose 
(1 ∣ ⊕ ⊕ ⊕ ). 
 3.4.3 The goal of the treatment is to maintain TSH con-
centration below 2.5 mU/l in the first trimester and below 
3 mU/l later in pregnancy (1 ∣ ⊕ ⚪ ⚪ ). 
 3.4.1–3.4.3 Evidence  
 There is currently no specific evidence for treatment 
schedules in pregnant women with CH. We therefore re-
fer to the guidelines of the American Thyroid Association 
and The Endocrine Society regarding the management of 
thyroid disease during pregnancy  [107–109] . 
 4.0 Outcomes of Treated Patients  
 4.1 Neurodevelopmental outcome  
 Neurocognition, behavior, memory, psychomotor, 
school progression, language, hearing, and 
visuospatial skills 
Recommendations  
 4.1.1 Psychomotor and language development as well 
as school progression should be monitored and recorded 
in all children with CH (1 ∣ ⊕ ⊕ ⚪ ). Clinicians should pay 
particular attention to developmental delays or learning 
difficulties and to attention problems in children with se-
vere CH (athyreosis, absent knee epiphyses at term, very 
low T 4 and very high TSH concentrations at diagnosis) or 
poor endocrine control, particularly during the first year, 
and in those from economically disadvantaged families 
(1 ∣ ⊕ ⊕ ⊕ ). 
 4.1.2 We suggest specialized stimulation of motor de-
velopment, if required, and a personalized educational 
plan if school progression is affected (2 ∣ ⊕ ⊕ ⚪ ). 
 4.1.3 Memory deficits may be corrected by targeted 
training (2 ∣ ⊕ ⊕ ⚪ ). 
 4.1.4 Concerns about behavior should be addressed 
from the time of diagnosis until school age (2 ∣ ⊕ ⊕ ⚪ ). 
 4.1.5 Adequate treatment throughout childhood is es-
sential, and overtreatment should be avoided (1 ∣ ⊕ ⊕ ⊕ ). 
 4.1.6 The determinants of remaining deficits require 
further study. 
 4.1.1–4.1.6 Evidence  
 With early and adequate treatment, intellectual dis-
ability (defined as an IQ <70) has disappeared from 
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cohorts screened for CH, and the mean global IQ is 
now 10 to 30 points higher in these patients than in the 
prescreening era  [1] . Some affected patients still have 
neurocognitive and behavioral sequelae of CH that 
persist into adolescence and adulthood and that are re-
lated to disease severity  [78, 82, 110, 111] . Cognitive 
outcome is related to age at treatment and L-T 4 dose 
 [90] ; school progression may be affected  [112] . Cogni-
tive outcome is related to the parents’ socioeducation-
al status  [49] . 
 Behavior scores on initial admission to school are 
within the normal range,  [89] and the perception of the 
impact of CH on behavior varies with age and differs be-
tween children and their parents  [113] . The impact of in-
forming teachers of the diagnosis of CH has not been in-
vestigated. Patients with CH have no increase in the risk 
of attention deficit-hyperactivity disorder but may have 
more sustained attention problems related to episodes of 
overtreatment  [114, 115] and, in severe cases, slower in-
formation processing  [116] . 
 Subtle and specific memory deficits and reduced hip-
pocampal volumes may be observed  [117] . There is also 
a risk of fine motor impairment  [118] . However, most 
early-treated patients are well integrated into society with 
no impairment in educational level  [46] . 
 Hearing, visual, verbal development 
Recommendations  
 4.1.7 Repeated (not just neonatal) hearing tests should 
be carried out before school age and as required (2 ∣ ⊕ ⊕ ⚪ ). 
 4.1.8 Assessing patients for evidence of visual process-
ing problems (not just visual acuity) is suggested 
(2 ∣ ⊕ ⚪ ⚪ ). 
 4.1.9 We recommend screening for delays in speech 
acquisition by the age of 3 years and propose speech ther-
apy as required (2 ∣ ⊕ ⊕ ⚪ ). 
 4.1.7–4.1.9 Evidence  
 Even after excluding patients with Pendred syndrome, 
a higher prevalence of hearing impairment has been ob-
served in patients with CH than in the reference popula-
tion, possibly necessitating the use of hearing aids in 
childhood. Substantial adverse effects on speech develop-
ment, school performance, and social interactions may 
occur if hearing impairment is undiagnosed  [119] . This 
impairment may result from the role of thyroid hormone 
in cochlear development and auditory function  [46, 120, 
121] . There is also a risk of visual processing problems 
 [10, 46] . 
 4.2 Health-related quality of life  
 Recommendations  
 4.2.1 Compliance with treatment should be promoted 
throughout life (1 ∣ ⊕ ⊕ ⊕ ). 
 4.2.2 In future studies of HrQOL, ‘focusing illusion’ 
should be considered (a form of stigmatization similar to 
‘labeling’ at school) (2 ∣ ⊕ ⚪ ⚪ ). 
 4.2.1–4.2.2 Evidence  
 There is a risk of a subtle decrease in HrQOL, particu-
larly in mental dimensions and if treatment is suboptimal 
 [46, 122, 123] . 
 4.3 Patient and professional education; 
compliance/adherence  
 Recommendations  
 4.3.1 Medical education about CH should be improved 
at all levels, with regular updates (1 ∣ ⊕ ⊕ ⊕ ). 
 4.3.2 We suggest identifying resources in the commu-
nity to which patients can be referred for continuing edu-
cation about self-management of their condition and to 
update their knowledge of CH. The education of both 
parents and patients is essential, with particular attention 
paid to the transition to adult care and management dur-
ing pregnancy (1 ∣ ⊕ ⊕ ⊕ ). 
 4.3.1–4.3.2 Evidence  
 The adherence of physicians to guidelines is low  [45] . 
Poor adherence with treatment and low treatment ade-
quacy are prevalent at all ages  [46, 124] . 
 4.4 Growth, puberty, and fertility  
 Recommendations  
 4.4.1 Adherence to treatment influences growth and 
should be promoted (1 ∣ ⊕ ⊕ ⊕ ). 
 4.4.2 Provided treatment is adequate, it is appropriate 
to provide patients and their parents with reassurance 
about growth, puberty, and fertility (1 ∣ ⊕ ⊕ ⊕ ). 
 4.4.1–4.4.2 Evidence  
 Length and height increase within normal limits in 
patients with adequately treated CH  [125] . Patients may 
be overweight in early childhood and adulthood  [46, 
126] . Head circumference may be greater than normal, 
but this reflects bone rather than brain development 
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 [127] . The onset of puberty, age at menarche, and men-
strual cycles are normal. Fecundity is generally normal, 
except in the most severely affected female patients  [128, 
129] . 
 4.5 Bone health  
 Recommendations  
 4.5.1 We recommend that patients with CH should be 
adequately treated with L-T 4 and consume 800–1200 mg 
of calcium daily, ideally from dietary sources, with calci-
um supplements added if dietary calcium intake is insuf-
ficient (2 ∣ ⊕ ⚪ ⚪ ). 
 4.5.1 Evidence  
 Thyroid hormones exert major effects on bone remod-
eling. Patients overtreated with L-T 4 display higher levels 
of bone resorption than of bone formation, leading to 
progressive bone loss. The goal of therapy is to render the 
patient euthyroid, with a normal TSH concentration. 
Only a few studies have evaluated the impact of long-term 
L-T 4 treatment on bone mineral density. Two studies re-
ported that bone mineral density in children and young 
adults with CH is within the normal range  [130, 131] . 
More data for patients treated with the currently used 
doses are required. 
 4.6 Metabolic and cardiovascular health  
 Recommendations  
 4.6.1 Weight should be closely monitored. Lifestyle in-
terventions, including diet and exercise, should be en-
couraged in individuals with CH (2 ∣ ⊕ ⚪ ⚪ ). 
 4.6.2 Optimal treatment of CH is essential for cardio-
vascular health (1 ∣ ⊕ ⚪ ⚪ ). 
 4.6.1–4.6.2 Evidence  
 Patients with CH have a higher risk of being over-
weight and, thus, of metabolic complications  [46] . In ad-
dition to the higher risk of congenital heart malforma-
tions  [61, 62] , there is a subtle increase in cardiovascular 
risk factors in young adults with CH, related to treatment 
adequacy  [132] . 
 5.0 Genetic Counseling and Antenatal 
Management  
 5.1 Criteria for genetic counseling  
 Recommendations  
 5.1.1 Genetic counseling should provide informa-
tion about the risk of recurrence of CH in a family with 
CH, based on family history and thyroid morphology. 
Each family with an affected child should have access to 
information on the two major forms of CH (dysgenesis 
and dyshormonogenesis) and should receive an expla-
nation of inheritance and recurrence rate. A certified 
geneticist or a genetic counselor (depending upon the 
Table 2.  Situations in which genetic counseling should be offered
I. Pregnant women
Positive family history for nonsyndromic CH
Dyshormonogenesis (previously affected child) (1∣⊕⊕⊕)
Dysgenesis (at least 1 member of the family) (2∣⊕⊕○)
Positive family history of syndromic CH with 
Neurological disorders, including unexplained mental 
retardation 
Deafness 
Congenital heart disease, surfactant deficiency syndrome 
Cleft palate 
Kidney malformations 
Any sign of Albright hereditary osteodystrophy (GNAS 
mutation) (1∣⊕⊕○) 
Unexplained abnormality of T4, T3, or TSH levels in family
members (mild forms of CH) (2∣⊕⊕○) 
II. Infant or child with CH (2∣⊕⊕○) 
Subject with 
Deafness 
Neurological signs (hypotonia, choreoathetosis, intellectual 
disability) 
Lung disorders (surfactant deficiency syndrome, interstitial 
lung disease) 
Congenital heart disease 
Cleft palate 
Kidney malformations 
Any sign of Albright hereditary osteodystrophy (GNAS 
mutation) 
Family history 
Consanguinity 
Kidney malformations 
Deafness 
Specific malformations (as listed above) 
Unexplained mental retardation despite adequate treatment 
of CH in family members 
Any sign of Albright hereditary osteodystrophy (GNAS 
mutation)
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organization of healthcare in the country concerned) 
should be made available in some cases. In such cases, 
given the current state of knowledge, we propose tar-
geted rather than general genetic counseling in the con-
text of certain clinical situations, described in  table  2 
(2 ∣ ⊕ ⊕ ⚪ ). 
 5.1.1 Evidence  
 In primary CH, about 80% of cases are due to thyroid 
dysgenesis and 20% are due to thyroid dyshormonogen-
esis. Thyroid dyshormonogenesis is caused by muta-
tions in genes encoding proteins involved in thyroid 
hormone synthesis: the  SCL5A5/NIS (iodide transport 
defect; OMIM No. 274400); pendrin,  SCL26A4/PDS 
(Pendred syndrome; OMIM No. 274600); thyroglob-
ulin,  TG (OMIM No. 274700); thyroid peroxidase,
 TPO (OMIM No. 274500); dual oxidase 2,  DUOX2 
(OMIM No. 607200); dual oxidase maturation factor 2, 
 DUOX2A (OMIM No. 274900); or iodotyrosine deio-
dinase,  IYD / DEHAL1 (OMIM No. 274800). These mu-
tations are inherited in an autosomal recessive manner 
and are associated with no other malformations, other 
than deafness in Pendred syndrome  [133] . Isolated thy-
roid dysgenesis (OMIM No. 218700) is generally a spo-
radic disease. However, three observations suggest a 
possible, as yet unknown genetic basis: (1) a higher rate 
of familial cases (>15 times higher) than would be ex-
pected by chance alone; (2) minor morphological thy-
roid abnormalities in euthyroid first-degree relatives of 
patients with thyroid dysgenesis; and (3) a high inci-
dence of associated extrathyroidal malformations  [61–
63, 134–137] . Specific genetic forms of syndromic and 
nonsyndromic thyroid dysgenesis and TSH resistance 
may be associated with mutations in the NK2 homeobox 
1 ( NKX2–1 , brain-lung-thyroid syndrome; OMIM No. 
610978); Forkhead box E1 ( FOXE-1 , Bamforth-Lazarus 
syndrome; OMIM No. 241850), Paired box gene 8 
( PAX8 ; OMIM No. 218700), NK2 homeobox 5 ( NKX2–
5 ; OMIM No. 225250), TSH receptor ( TSHR ; OMIM 
No. 275200); and Gs α; ( GNAS , pseudohypoparathy-
roidism type 1A; OMIM No. 103580) genes  [133, 138] 
( table 3 ). 
Table 3.  Genetic diagnosis to detect the individual molecular basis of CH
Thyroid morphology, as assessed by 
ultrasonography and/or scintigraphy
 Family history 
consanguinity or siblings/cousins 
with CH
parents 
with CH 
Isolated CH Normally located thyroid with normal 
perchlorate discharge test
TSH-R (if hypoplasia), 
TG (if goiter, low TG level)
PAX8 
Normally located thyroid with
abnormal perchlorate discharge test 
(ie, iodide organification defects)
TPO, DUOX2/DUOXA2 +/– TG
Normall y located thyroid on 
ultrasonography, with no iodide uptake 
on scintigraphy
SCL5A5/NIS, TSH-R (if hypoplasia)
Syndromic CH
Deafness Normally located thyroid SCL26A4/PDS
Short stature, obesity, hypocalcemia Normally located thyroid GNAS 
Cleft palate, ‘spiky’ hair Athyreosis (hypoplasia) FOXE1 (no mutations described in
patients with ectopic or normally sized
and sited thyroid gland to date)
Kidney agenesis or any malformation 
of the genitourinary tract
Athyreosis, ectopic thyroid gland, 
normally located thyroid +/– hypoplasia
PAX8 PAX8 
Choreoathetosis or neurological 
disease
Normally located thyroid, hypoplasia 
(athyreosis)
NKX2–1 (no mutations described
in ectopic cases so far)
NKX2–1 
Lung disorders (surfactant deficiency 
syndrome at term, interstitial lung 
disease)
Normally located thyroid, hypoplasia 
(athyreosis)
NKX2–1 (no mutations described
in ectopic cases so far)
NKX2–1 
Cardiac defects Ectopy (athyreosis) NKX2–5 NKX2–5
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 5.2 Molecular biology in the diagnosis and 
management of CH  
 Recommendations  
 5.2.1 Careful phenotypic description of CH patients 
(including morphological analysis of the thyroid gland) 
is required, and we suggest that any syndromic associa-
tion should be studied genetically to identify new genes 
involved in CH and to ensure that healthcare staff
are in a position to offer appropriate genetic counsel-
ing. The presence of familial cases of dysgenesis should 
lead to a search for  TSHR and  PAX8 gene mutations 
(2 ∣ ⊕ ⊕ ⚪ ). 
 The genetic diagnosis of CH may facilitate the target-
ing of specific interdisciplinary follow-up and supportive 
care for patients (1 ∣ ⊕ ⊕ ⚪ ). The relevant features to con-
sider are listed in  table 3 . 
 5.2.1 Evidence  
 Molecular biology techniques can identify the cause 
of CH on the basis of family history and thyroid mor-
phology. The identification of a  NKX2–1 mutation im-
plies that special attention should be paid to neurologi-
cal development and to lung disease in the follow-up of 
affected children  [139, 140] . The identification of a 
 FOXE1 mutation implies that special attention should 
be paid to neurological development  [141] . The identi-
fication of a  PAX8 mutation should lead to kidney and 
urinary tract ultrasound and, probably, to the monitor-
ing of renal function if malformations are found [142] . 
The identification of a  SLC26A4/PDS mutation implies 
that special attention should be paid to the hearing of the 
child  [143] . The identification of a  TG or  TPO mutation 
implies a risk of thyroid cancer within the goiter in 
adulthood, as demonstrated by long-term follow-up 
studies in extremely rare published cases  [133, 144] . It is 
unclear whether the thyroid cancer is gene-specific or 
related to goiter development. The identification of a 
 GNAS mutation should lead the clinician to focus on 
other potentially associated endocrine and nonendo-
crine disorders  [145] . Despite intensive and focused re-
search, mutations in these genes have been found in few-
er than 10% of CH patients to date, and the usual discor-
dance between monozygotic twins  [136] remains 
unexplained. 
 5.3 Potential indications for antenatal diagnosis, 
screening methods for fetal hypothyroidism, 
management and criteria for fetal treatment
in utero  
 Recommendations  
 5.3.1 We recommend antenatal diagnosis in cases of goi-
ter fortuitously discovered during systematic ultrasound 
examination of the fetus, in relation to thyroid dyshor-
monogenesis (1 ∣ ⊕ ⊕ ⊕ ); a familial recurrence of CH due to 
dyshormonogenesis (25% recurrence rate) (1 ∣ ⊕ ⊕ ⊕ ); and 
known defects of genes involved in thyroid function or de-
velopment with potential germline transmission (1 ∣ ⊕ ⊕ ⚪ ). 
Special issues should be considered for syndromic cases 
with potential mortality and possible germline mosaicism 
(as for  NKX2–1 gene mutation/deletion and severe pulmo-
nary dysfunction with possible transmission via germline 
mosaicism). In such circumstances, the discussion of the 
prenatal diagnosis should be open. The therapeutic man-
agement of affected fetuses should comply with the laws in 
force in the country concerned (1 ∣ ⊕ ⊕ ⚪ ). The familial re-
currence of CH due to dysgenesis (2% of familial occur-
rences) requires further study to determine the feasibility 
and clinical relevance for antenatal detection. 
 5.3.2 For the evaluation of fetal thyroid volume, we 
recommend ultrasound scans at 20 to 22 weeks gestation 
to detect fetal thyroid hypertrophy and potential thyroid 
dysfunction in the fetus. Goiter or an absence of thyroid 
tissue can also be documented by this technique. Mea-
surements should be made as a function of GA, and thy-
roid perimeter and diameter should be measured to doc-
ument goiter (1 ∣ ⊕ ⊕ ⊕ ). 
 5.3.3 We recommend cordocentesis, rather than am-
niocentesis, as the reference method for assessing fetal 
thyroid function. Norms have been established as a
function of GA. This examination should be carried out 
only if prenatal intervention is considered (see below) 
(1 ∣ ⊕ ⊕ ⊕ ). 
 5.3.4 In most cases, fetal thyroid function can be in-
ferred from context and ultrasound criteria, and fetal 
blood sampling is, therefore, only exceptionally required 
(2 ∣ ⊕ ⊕ ⚪ ). 
 5.3.5 In a euthyroid pregnant woman, a large goiter in 
the fetus with progressive hydramnios and a risk of pre-
mature labor and delivery and/or concerns about trache-
al occlusion are criteria in favor of fetal treatment in ute-
ro (1 ∣ ⊕ ⊕ ⚪ ). 
 5.3.6 In a hypothyroid pregnant woman, the initial ap-
proach should be to treat the pregnant woman, rather 
than the fetus, with L-T 4 (1 ∣ ⊕ ⊕ ⚪ ). 
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 5.3.7 For goitrous nonimmune fetal hypothyroidism 
leading to hydramnios, intra-amniotic injections of 
L-T 4 have been reported to decrease the size of the fetal 
thyroid gland. However, experience with this procedure 
is limited, and the risk of provoking premature labor or 
infections should be evaluated with care. Thus, follow-
up studies are very important to determine the efficacy 
and possible adverse long-term consequences of medi-
cal interventions on the fetus. Such interventions should 
be performed only by multidisciplinary specialist teams 
(pediatric endocrinologists, adult endocrinologists for 
the pregnant mother, neonatologists, and obstetricians 
with experience in antenatal care and procedures) 
(1 ∣ ⊕ ⊕ ⊕ ). 
 5.3.8 Studies have confirmed the feasibility and safety 
of intra-amniotic L-T 4 injection and strongly suggest 
that this treatment is effective for decreasing goiter size. 
However, none of the many L-T 4 regimens used ensures 
euthyroidism at birth. It is therefore not possible to for-
mulate guidelines from current data. The expert panel 
proposes the use of 10 μg/kg estimated fetal weight/15 
days in the form of intra-amniotic injections. The risks 
to the fetus and the psychological burden on the parents 
should be factored into the risk/benefit evaluation 
(2 ∣ ⊕ ⚪ ⚪ ). 
 5.3.9 Determination of the indications and optimal 
modes of prenatal treatment for nonimmune fetal goi-
trous hypothyroidism will require larger, well-designed 
studies that would be best conducted via international 
co-operation between multidisciplinary medical teams. 
Alternative ways of treating the fetus by administering 
drugs to the mother should also be investigated 
(2 ∣ ⊕ ⚪ ⚪ ). 
 5.3.1–5.3.9 Evidence  
 Recent advances in fetal imaging techniques (ultraso-
nography) and fetal hormonology have made it possible 
to identify thyroid function disorders in the fetus that 
could potentially be treated in utero by administering 
drugs to the mother. Several interventions have also been 
proposed for improving the fetal outcomes of fetal hypo-
thyroid disorders by considering the fetus as the patient 
to be treated and gaining direct access to the amniotic 
cavity. These approaches range from public health inter-
ventions with clear benefits and negligible risks, such as 
increasing the iodine intake of all pregnant women, to 
procedures with a much less clear benefit-to-risk ratio, 
such as cordocentesis for determining thyroid function in 
a fetus with goiter and repeated intra-amniotic injections 
of L-T 4  [146–152] ( table 4 ). 
 Conclusions 
 Patients with CH benefit from neonatal screening, 
which makes it possible to initiate essential replacement 
therapy immediately. This consensus highlights the need 
to identify clear cutoff points for CH screening, without 
increasing the number of false-positive results. However, 
the results of long-term prospective studies in subjects 
with false-positive results are not yet available for the for-
mulation of evidence-based recommendations for diag-
nosis and management. Based on current outcome data, 
an immediate treatment should be initiated, and it ap-
pears necessary to maintain adequate L-T 4 treatment 
throughout the lifespan for most patients, with a particu-
lar emphasis on treatment in the first years of life and of 
treatment optimization in pregnant women with CH. 
Careful neuro developmental and neurosensory evalua-
tions should be started early in life and repeated at impor-
tant critical developmental phases, taking into account 
disease severity at diagnosis and providing appropriate 
interventions as required. Subsequent efforts should fo-
cus on educating both patients and caregivers to ensure 
that adequate treatment is continued into adulthood. Fu-
ture research should aim to improve our understanding 
of the pathophysiology of this heterogeneous disorder 
and to determine whether knowledge of the specific de-
fect in thyroid development or function is likely to im-
prove patient care and outcomes. 
Table 4.  Screening, prevention, and management of fetal hypothy-
roidism
Adequate iodine intake should be ensured for all pregnant 
women (250 μg/d)
For women with a personal or family history of thyroid disease, 
serum TSH and FT4 concentrations should be determined before 
pregnancy, at the start of pregnancy, and during pregnancy
On ultrasonography at about 22 and 32 weeks gestation, fetal 
thyroid diameter and circumference should be measured; if 
above the 95th percentile for GA, a fetal thyroid disorder should 
be considered
If a pregnant woman is treated with L-T4, care should be taken 
to ensure an appropriate increase in dose during the course of 
the pregnancy
If fetal goiter is documented, cordocentesis and fetal serum 
FT4 and TSH determinations should be considered, and
intra-amniotic L-T4 injections should be administered if severe 
hypothyroidism is diagnosed and progressive hydramnios 
develops
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